Browsing: said in a statement. “We look forward to filing with regulators globally and remain committed to doing our part to help end the COVID-19 pandemic with a vaccine for adults and children of all ages.”
Moderna reported that its two-dose vaccine generated virus-neutralizing antibodies in children, and safety was comparable to what was previously seen in clinical trials of adolescents and adults.